Vivani Medical (VANI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Vivani Medical, Inc. (NASDAQ: VANI - Get Free Report) was the recipient of a significant decrease in short interest in February. As of February 27th, there was short interest totaling 290,597 shares, a decrease of 25.4% from the February 12th total of 389,363 shares. Approximately 0.7% of the company's stock are sold short. Based on an
VYNE Therapeutics (NASDAQ: VYNE - Get Free Report) and Vivani Medical (NASDAQ: VANI - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk. Volatility and Risk VYNE Therapeutics has a
| Health Care Technology Industry | Healthcare Sector | Adam Mendelsohn CEO | XDUS Exchange | US92854B1098 ISIN |
| US Country | 37 Employees | - Last Dividend | 19 Aug 2022 Last Split | 19 Nov 2014 IPO Date |
Vivani Medical, Inc. stands as a clinical-stage enterprise committed to the innovation of medical solutions designed to address chronic diseases that currently suffer from a high degree of unmet medical needs. Positioned at the forefront of medical technology, Vivani Medical is dedicated to transforming the treatment landscape for these conditions. With its headquarters nestled in Emeryville, California, the company signifies a hub of innovation aimed at redefining the standards of patient care through groundbreaking medical devices.
Vivani Medical is pioneering the development of a portfolio of miniature drug implants. These implants are ingeniously designed to deliver drugs into the body with minimal fluctuations in dose. This cutting-edge approach ensures a more consistent delivery of medication, targeting chronic diseases with precision and improving the overall effectiveness of treatment regimens. The focus is on enhancing patient convenience and compliance, significantly impacting long-term disease management.
In a bold venture into the realm of visual impairment, Vivani Medical is developing implantable visual prostheses devices. These devices herald a new era in artificial vision, offering a beacon of hope for blind individuals. By providing a form of useful artificial vision, these prostheses aim to significantly enhance the quality of life for those affected by blindness. The innovation encapsulates the company's dedication to tackling conditions with substantial unmet needs, offering groundbreaking solutions that extend beyond the conventional treatment paradigms.